BioSpace15m
Explainer: The Thriving Shadow Market of GLP-1s for Weight Loss
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA
The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
WRAL6d
Weight loss pill could replace injections, would be transformative for millions
A breakthrough in weight loss medication is on the horizon. While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient ...
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
WDRB13h
The 2 sides of Ozempic — weight loss success stories and health nightmares in Kentucky
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Is Novo Nordisk's Bottom Here? Oversold Status Below 10Y P/E Lows
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
AOL6d
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
To do so, Novo Nordisk’s CFO, Karsten Munk Knudsen, says the company is now looking at the next generation of weight loss drugs ... for high[ly] efficacious products, it would be patients ...
Nasdaq9d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead this lucrative and fast-growing market. However, Novo Nordisk (NYSE ...